On Oct. 17, 2025, Chinese biotech Hansoh Pharma said it had signed a license agreement worth up to $1.45 billion with Roche for an investigational treatment of colorectal cancer and other solid tumours.

Hansoh Pharma units Shanghai Hansoh Biomedical and Changzhou Hansoh Pharmaceutical will grant Roche subsidiary F. Hoffmann-La Roche an exclusive worldwide licence to develop, manufacture and commercialise the product.

The license excludes rights in the Chinese Mainland, Hong Kong, Macau and Taiwan. The licensors will receive an upfront payment of $80 million and be eligible to receive up to $1.45 billion in milestone payments associated with the development, regulatory approval and commercialisation of the product, among others.